Status:
RECRUITING
Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University
Conditions:
Malignant Tumour
Eligibility:
All Genders
18-90 years
Phase:
EARLY_PHASE1
Brief Summary
As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosime...
Detailed Description
The boom in radiopharmaceuticals continues to persist, including their driving effects in the field of immunotherapy. CD73 (ecto-5'-nucleotidase), a key purine metabolic enzyme, catalyzes the conversi...
Eligibility Criteria
Inclusion
- Signed informed consent and be able to follow up.
Exclusion
- Pregnant or lactational women; who suffered from severe hepatic and renal insufficiency.
Key Trial Info
Start Date :
March 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06995976
Start Date
March 1 2025
End Date
March 1 2026
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005